Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Phase: Phase 1
Diagnosis: Multiple Myeloma
NCT ID: NCT01718899
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-014
The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.
Massachusetts General Hospital, Beth-Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital
Noopur Raje, MD,
Massachusetts General Hospital
David Avigan, MD,
Beth Israel Deaconess Medical Center
Paul Richardson, MD,
Dana-Farber Cancer Institute
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
- Patient has confirmed clinical diagnosis of SMM according to a definition derived
from the International Myeloma Working Group (IMWG) definition: serum M-protein ≥3
g/dL or bone marrow clonal plasma cells (BMPC) >10%, or both, along with normal organ
and marrow function (CRAB) within 4 weeks before baseline.
- C: Absence of hypercalcemia, evidenced by a calcium <10.5 mg/dL.
- R: Absence of renal failure, evidenced by a creatinine <2.0 mg/dL or calculated
creatinine clearance (using the Modification of Diet in Renal Disease [MDRD] formula)
- A: Absence of anemia, evidenced by a hemoglobin >10 g/dL.
- B: Absence of lytic bone lesions on standard skeletal survey.
- Patient is at higher than average risk of progression to active MM, defined as having
2 or more of the following features:
- Serum monoclonal (M)-protein ≥3 g/dL.
- BMPC >10%.
- Abnormal serum free light chain (FLC) ratio (0.26-1.65).
- Patient has a life expectancy of greater than 6 months
- Patient is human leukocyte antigen (HLA)-A2 positive.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L
and an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline.
- Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an
alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5× the upper limit of
normal (ULN) within 2 weeks before baseline.
- If of child-bearing potential, patient agrees to use adequate birth control measures
during study participation.
- If a female of child-bearing potential, patient has negative urine pregnancy test
results within 2 weeks before baseline and is not lactating.
- Patient (or his or her legally accepted representative) has provided written informed
consent to participate in the study.
- Patient has symptomatic multiple myeloma, as defined by any of the following:
- Lytic lesions or pathologic fractures.
- Anemia (hemoglobin <10 g/dL).
- Hypercalcemia (corrected serum calcium >11.5 mg/dL).
- Renal insufficiency (creatinine >2 mg/dL).
- Other: symptomatic hyperviscosity, amyloidosis.
- Patient has a history of a prior malignancy within the past 5 years (excluding
resected basal cell carcinoma of the skin or in situ cervical cancer).
- Patient has abnormal cardiac status, evidenced by any of the following:
- New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).
- Myocardial infarction within the previous 6 months.
- Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment.
- Patient is receiving any other investigational agent.
- Patient has a current active infectious disease or positive serology for human
immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
- Patient has a history of or current auto-immune disease.
- Patient has been vaccinated with live attenuated vaccines within 4 weeks before study